Xdapa 10mg Tablet contains dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting SGLT2 in the proximal renal tubules, dapagliflozin reduces glucose reabsorption, promoting increased urinary glucose excretion and thereby lowering plasma glucose levels. This mechanism aids in improving glycemic control as an adjunct to diet and exercise. Xdapa 10mg is typically prescribed for adult patients inadequately controlled on diet and exercise alone or in combination with other antidiabetic agents such as metformin. Clinical studies have demonstrated its efficacy in reducing HbA1c, fasting plasma glucose, and postprandial glucose levels. Additionally, dapagliflozin has shown benefits in reducing body weight and systolic blood pressure, contributing to overall cardiovascular risk reduction. The medication is administered orally once daily, with or without food. Common adverse effects include genital mycotic infections, urinary tract infections, and increased urination. It is contraindicated in patients with severe renal impairment, end-stage renal disease, or on dialysis. Caution is advised in patients with a history of hypersensitivity to dapagliflozin or related compounds. Regular monitoring of renal function and glycemic parameters is recommended during therapy to ensure safety and efficacy.